Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Authors:
- E. V. ShlyakhtoESE. V. Shlyakhto
- I. I. DedovIDI. I. Dedov
- V. N. SerovVSV. N. Serov
- G. T. SukhikhGSG. T. Sukhikh
- G. P. ArutyunovGAG. P. Arutyunov
- I. A. SuchkovISI. A. Suchkov
- O. M. DrapkinaODO. M. Drapkina
- O. N. TkachevaOTO. N. Tkacheva
- Ya. A. OrlovaYOYa. A. Orlova
- I. I. BaranovIBI. I. Baranov
- E. N. AndreevaEAE. N. Andreeva
- S. V. YurenevaSYS. V. Yureneva
Open Access
- 18 January 2026
- journal article
- practice guideline
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Abstract
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.Keywords
This publication has 164 references indexed in Scilit:
- Lipoprotein(a), Menopausal Hormone Therapy, and Risk of Coronary Heart Disease in Postmenopausal IndividualsJAMA Cardiology, 2022
- Sex Differences in Blood Pressure Trajectories Over the Life CourseJAMA Cardiology, 2020
- Venous Thrombosis and Conjugated Equine Estrogen in Women Without a UterusArchives of internal medicine (1960), 2006
- Estrogen Plus Progestin and Risk of Venous ThrombosisJAMA, 2004
- Effect of Estrogen Plus Progestin on Stroke in Postmenopausal WomenJAMA, 2003
- Cardiovascular Disease Outcomes During 6.8 Years of Hormone TherapyJAMA, 2002
- Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal WomenArchives of internal medicine (1960), 2000
- Hormone Replacement Therapy and Peripheral Arterial DiseaseArchives of internal medicine (1960), 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal WomenJAMA, 1995